Rifaximin, a semisynthetic rifamycin which is nonabsorbable in the gastrointestinal tract, has been available in Europe and other countries for several years and has recently been approved in the US for treatment of traveler's diarrhea. This volume brings together all of the available microbiology, pharmacology and clinical aspects of the drug in 12 commissioned monographic reviews by 30 internationally renowned scientists. The topics addressed include the pathogenesis of gastrointestinal bacterial overgrowth; the role of rifaximin in the management of hepatic encephalopathy; and management of diverticular disease.http://www.amazon.com/Rifaximin-Absorbed-Antibiotic-Pharmacology-Clinical/dp/3805578911/ref=sr_1_1?ie=UTF8&s=books&qid=1251634802&sr=1-1